Johnson & Johnson (JNJ) has held relatively steady in the very short term, with the stock roughly flat over the past day but ...

Johnson & Johnson's JNJ Immunology franchise remains one of its most important businesses, even as it undergoes a transition ...

Johnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the ...

JNJ stock faces pressure despite strong earnings and dividend growth. Explore how s&p today trends and sector rotation impact ...

Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliver peak sales north ...

Passive income is the cash flow that arrives whether you are working, sleeping, or watching the market churn. For investors ...

Johnson & Johnson is scheduled to announce its earnings on Tuesday, April 15, 2025. Analysts expect earnings of $2.59 per share on revenue of $21.6 billion for the current year, compared to $2.71 per ...

CHONGQING, CHINA - JULY 13: In this photo illustration, a smartphone displaying the logo of Johnson & Johnson (NYSE: JNJ), a leading American multinational corporation known for pharmaceuticals, ...

The combination showed efficacy exceeding that of either monotherapy ...

J&J investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease: Chicago, Illinois Thursd ...